Quarterly ResultAug 13, 2026, 04:45 PM
Cadrenal Therapeutics Q2 Loss Narrows, Cites Going Concern Doubt
AI Summary
Cadrenal Therapeutics reported a net loss of $(5.82) million for the six months ended June 30, 2026, an improvement from $(7.51) million in the prior year period. Despite the reduced loss, the company's cash and cash equivalents declined to $2.39 million, leading management to express "substantial doubt" about its ability to continue as a going concern. The company also highlighted recent asset acquisitions for its pipeline, including frunexian and CAD-1005, and capital raised through warrant inducements and ATM sales.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $(5.82) million, an improvement from $(7.51) million year-over-year.
- Net loss per common share improved to $(2.19) for the six months ended June 30, 2026, from $(3.95) in the prior year.
- Cash and cash equivalents decreased to $2.39 million as of June 30, 2026, from $4.01 million at December 31, 2025.
- Management expressed "substantial doubt" about the company's ability to continue as a going concern.
- Proceeds from warrant inducements totaled $2.23 million for the six months ended June 30, 2026.
- Proceeds from at-the-market (ATM) common stock sales were $1.38 million for the six months ended June 30, 2026.
- Acquired frunexian and EP-7327 assets from eXIthera for $50,000 upfront in September 2025.
- Acquired CAD-1005 and CAD-2000 assets from Veralox for $200,000 upfront in December 2025.
Price Impact
More from CVKD